1. SARS-CoV-2 infection in patients with β-thalassemia: The French experience
- Author
-
Imane Agouti, Laurent Pascal, Gonzalo De Luna, Isabelle Thuret, and Estelle Jean-Mignard
- Subjects
medicine.medical_specialty ,Cirrhosis ,Iron Overload ,Thalassemia ,Clinical Biochemistry ,Population ,Neutropenia ,Hydroxycarbamide ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Adverse effect ,education ,Child ,education.field_of_study ,business.industry ,SARS-CoV-2 ,Biochemistry (medical) ,beta-Thalassemia ,COVID-19 ,Infant ,Hematology ,Middle Aged ,medicine.disease ,Pneumonia ,chemistry ,Original Article ,Deferiprone ,business ,medicine.drug - Abstract
INTRODUCTION: Because of iron overload complications, thrombosis and infectious predisposition, patients with severe forms of thalassemia are likely to be at increased risk of COVID-19 complications. RESULTS: A national survey conducted during the year 2020 across the French reference centers for hemoglobinopathies identified 16 cases of COVID-19 confirmed by RT-PCR in beta-thalassemia patients. Their age ranged from 11 months to 60 years. 15 patients were transfusion-dependent and 6 were splenectomized. Concerning iron overload related complications, none had diabetes or cirrhosis and only one had experienced heart failure. All 4 pediatric patients were pauci-symptomatic during the viral episode. Three patients (41, 49 and 57 years old) developed COVID-19 pneumonia requiring oxygen therapy without the need for mechanical ventilation. Neutropenia (absolute neutrophils count
- Published
- 2021